CD46 knock-out using CRISPR/Cas9 editing of hTERT immortalized human cells modulates complement activation


CD46 knock-out using CRISPR/Cas9 editing of hTERT immortalized human cells modulates complement activation


Evercyte Logo 150

White Paper | Evercyte GmbH

Abstract Summary

The kidney is especially sensitive to diseases associated with over activation of the complement system. While most of these diseases affect kidney glomeruli and the microvasculature, there is also evidence for tubulointerstitial deposition of complement factors.

To learn more about Evercyte’s CD46 knock-out using CRISPR/Cas9 editing of hTERT immortalized human cells modulates complement activation, please click on the White Paper below:

WHITE PAPER

WHITE PAPER

Resources

Click on CD46 knock-out using CRISPR/Cas9 editing of hTERT immortalized human cells modulates complement activation for other information.
Click on Evercyte to contact the company directly.

Sources: Matthias Weiser, Teresa Francisci – Evercyte GmbH, Vienna, Austria; Daniel Lackner, Tilmann Buerckstuemmer – Horizon Genomics GmbH; Kamilla Wasner, Markus Wahrmann, Georg A. Bohmig – Department of Medicine III. Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria; Wolf Eilenberg, Anton Stift – Department of Surgery, Medical University of Vienna, Vienna, Austria; Johannes Grillari – Evercyte GmbH, Vienna, Austria / Department of Biotechnology, BOKU Vienna, Vienna, Austria / Austrian Cluster for Tissue Regeneration, Vienna Austria / Christian Doppler Laboratory for Biotechnology of Skin Ageing, Vienna, Austria; Redina-Griari-Voglauer – Evercyte GmbH, Vienna, Austria / Department of Biotechnology, BOKU Vienna, Vienna, Austria / Austrian Cluster for Tissue Regeneration, Vienna Austria.


Supplier Information
Supplier: Evercyte GmbH
Address: Leberstrasse 20, 1110 Vienna, Austria
Tel: +43 699 10 709 401
Website: http://www.evercyte.com


Comments are closed.